| GP IIb/IIIa inhibitors in coronary artery disease management: what the latest trials tell us. | |
| | |
MedLine Citation:
|
PMID: 11765119 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Recent clinical trials have refined our understanding of how the glycoprotein (GP) IIb/IIIa inhibitors should best be used. These trials examined whether there are clinical differences between agents, whether empiric use of GP IIb/IIIa inhibitors in acute coronary syndromes is justified, and whether these drugs might allow for early invasive management in acute coronary syndromes. |
| | |
Authors:
|
D P Chew; D J Moliterno |
Related Documents
:
|
10692739 - Unstable angina: a review and practical guide to management. 10680279 - Glycoprotein iib/iiia inhibitors in acute coronary syndromes. 11322919 - Systematic review of hirudin in acute coronary syndromes and percutaneous coronary inte... 10219559 - Severe cutaneous cholesterol emboli syndrome after coronary angiography. 21533869 - Should we consider mmf therapy after rituximab for nephrotic syndrome? 16352229 - Conservative management of a large oesophageal haematoma as a complication of systemic ... 6844659 - The psychiatry of vertebro-basilar insufficiency with the report of a case. 12613409 - Carpal tunnel syndrome: current theory, treatment, and the use of b6. 9147879 - Rett syndrome in northern tuscany (italy): family tree studies. |
Publication Detail:
|
Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Review |
Journal Detail:
|
Title: Cleveland Clinic journal of medicine Volume: 68 ISSN: 0891-1150 ISO Abbreviation: Cleve Clin J Med Publication Date: 2001 Dec |
Date Detail:
|
Created Date: 2001-12-17 Completed Date: 2002-01-03 Revised Date: 2013-05-24 |
Medline Journal Info:
|
Nlm Unique ID: 8703441 Medline TA: Cleve Clin J Med Country: United States |
Other Details:
|
Languages: eng Pagination: 1017-23 Citation Subset: IM |
Affiliation:
|
Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, OH 44195, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Acute Disease Angina, Unstable / drug therapy Angioplasty, Balloon, Coronary Antibodies, Monoclonal / administration & dosage, therapeutic use Anticoagulants / administration & dosage, therapeutic use* Atherectomy Clinical Trials as Topic* Coronary Disease / drug therapy*, surgery, therapy Fibrinolytic Agents / administration & dosage, therapeutic use* Humans Immunoglobulin Fab Fragments / administration & dosage, therapeutic use Myocardial Infarction / drug therapy Peptides / administration & dosage, therapeutic use Placebos Platelet Aggregation Inhibitors / administration & dosage, therapeutic use* Platelet Glycoprotein GPIIb-IIIa Complex / antagonists & inhibitors* Stents Syndrome Time Factors Treatment Outcome Troponin T / blood Tyrosine / administration & dosage, analogs & derivatives*, therapeutic use |
| Chemical | |
Reg. No./Substance:
|
0/Antibodies, Monoclonal; 0/Anticoagulants; 0/Fibrinolytic Agents; 0/Immunoglobulin Fab Fragments; 0/Peptides; 0/Placebos; 0/Platelet Aggregation Inhibitors; 0/Platelet Glycoprotein GPIIb-IIIa Complex; 0/Troponin T; 0/eptifibatide; 144494-65-5/tirofiban; 55520-40-6/Tyrosine; X85G7936GV/abciximab |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Oral contraceptives: an update on health benefits and risks.
Next Document: Our new understanding of pulmonary alveolar proteinosis: what an internist needs to know.